Document:

EX-10.10

 Exhibit 10.10 

RESTRICTED STOCK UNIT AWARD AGREEMENT 

UNDER THE GREENLIGHT BIOSCIENCES, INC. 

2021 EQUITY AND INCENTIVE PLAN 
  

			
	 Name of Grantee:
	  	                                      
                                         
         
		
	 No. of Restricted Stock Units:
	  	                                      
      
		
	 Grant Date:
	  	                                      
      

 Pursuant to the GreenLight Biosciences, Inc. 2021 Equity and Incentive Plan (as amended through the date
hereof, the “Plan”), GreenLight Biosciences, Inc. (the “Company”) hereby grants an award of the number of Restricted Stock Units listed above (the “Award”) to the Grantee named above. Each
Restricted Stock Unit shall relate to one share of common stock, par value $0.0001 per share, of the Company (the “Stock”). 

1. Restrictions on Transfer of Award. This Award may not be sold, transferred, pledged, assigned or otherwise encumbered or disposed of
by the Grantee, and any shares of Stock issuable with respect to the Award may not be sold, transferred, pledged, assigned or otherwise encumbered or disposed of until shares of Stock have been issued to the Grantee in accordance with the terms of
the Plan and this Agreement with respect to Restricted Stock Units that have vested as provided in Section 2 of this Agreement. 

2. Vesting of Restricted Stock Units. Restricted Stock Units will vest on the Vesting Date or Dates specified in the following schedule,
and in the amounts set forth on such schedule, so long as the Grantee remains in a Service Relationship (as defined in the Plan) through the relevant Vesting Date. 
  

			
	 Number of

Restricted Stock Units Vesting
	  	 Vesting Date

	_____________ (___%)	  	_____________
	_____________ (___%)	  	_____________
	_____________ (___%)	  	_____________
	_____________ (___%)	  	_____________

 3. Termination of Service Relationship. If the Grantee’s Service Relationship terminates for any
reason (including death or disability) prior to the satisfaction of the vesting conditions set forth in Section 2 above, any Restricted Stock Units that have not vested as of such date shall automatically and without notice
terminate and be forfeited, and neither the Grantee nor any of Grantee’s successors, heirs, assigns, or personal representatives will thereafter have any further rights or interests in such unvested Restricted Stock Units. 

 4. Issuance of Shares of Stock. As soon as practicable following each Vesting Date
(but in no event later than two and one-half months after the end of the year in which the Vesting Date occurs), the Company shall issue to the Grantee the number of shares of Stock equal to the aggregate
number of Restricted Stock Units that have vested pursuant to Section 2 of this Agreement on such date and the Grantee shall thereafter have all the rights of a stockholder of the Company with respect to such shares. 

5. No Rights as a Stockholder. The Grantee shall not have any right in, or with respect to, any of the shares of Stock issuable under
this Award unless and until Restricted Stock Units vest and shares of Stock are issued to the Grantee pursuant to Section 4 above. 

6. Incorporation of Plan. Notwithstanding anything herein to the contrary, this Agreement shall be subject to and governed by all the
terms and conditions of the Plan, including the powers of the Administrator set forth in Section 3(b) of the Plan. In the event of any conflict between the terms hereof and those of the Plan, the latter shall prevail. Capitalized terms in this
Agreement shall have the meaning specified in the Plan, unless a different meaning is specified herein. 
 7. Tax Withholding. The
Grantee shall, not later than the date as of which the receipt of this Award becomes a taxable event for Federal income tax purposes, pay to the Company or make arrangements satisfactory to the Administrator for payment of any Federal, state, and
local taxes required by law to be withheld on account of such taxable event. The Company shall have the authority to cause any required tax withholding obligation to be satisfied, in whole or in part, by (i) withholding from shares of Stock to
be issued to the Grantee a number of shares of Stock with an aggregate Fair Market Value that would satisfy the withholding amount due; or (ii) causing its transfer agent to sell from the number of shares of Stock to be issued to the Grantee,
the number of shares of Stock necessary to satisfy the Federal, state and local taxes required by law to be withheld from the Grantee on account of such taxable event. 

8. Section 409A of the Code. This Agreement shall be interpreted in such a manner that all provisions relating to the
settlement of the Award are exempt from the requirements of Section 409A of the Code as “short-term deferrals” as described in Section 409A of the Code. 

9. No Obligation to Continue Service Relationship. Neither the Company nor any Subsidiary is obligated by or as a result of the Plan or
this Agreement to continue the Grantee’s Service Relationship with the Company or a Subsidiary, and neither the Plan nor this Agreement shall interfere in any way with the right of the Company or any Subsidiary to terminate the Grantee’s
Service Relationship at any time. 
 10. Integration. This Agreement and the Plan constitute the entire agreement between the parties
with respect to this Award and supersede all prior agreements and discussions between the parties concerning this Award. 
 11. Data
Privacy Consent. In order to administer the Plan and this Agreement and to implement or structure future equity grants, the Company, its subsidiaries and affiliates and certain agents thereof (together, the “Relevant Companies”)
may process any and all personal or professional data, including but not limited to Social Security or other identification number, home address and telephone number, date of birth and other information that is necessary or desirable for the
administration of the Plan and/or this Agreement (the “Relevant Information”). By entering into this Agreement, the Grantee (i) authorizes each Relevant 

  
 2 

 
Company to collect, process, register and transfer to each other Relevant Company all Relevant Information; (ii) waives any privacy rights the Grantee may have with respect to the Relevant
Information; (iii) authorizes the Relevant Companies to store and transmit such information in electronic form; and (iv) authorizes the transfer of the Relevant Information to any jurisdiction which a Relevant Company considers
appropriate. The Grantee shall have access to, and the right to change, the Relevant Information. Relevant Information will only be used in accordance with applicable law. 

12. Notices. Notices hereunder shall be mailed or delivered to the Company at its principal place of business and shall be mailed or
delivered to the Grantee at the address on file with the Company or, in either case, at such other address as one party may subsequently furnish to the other party in writing. 

 

			
	GREENLIGHT BIOSCIENCES, INC.
		
	By:	 	  

		 	Title:

 The foregoing Agreement is hereby accepted and the terms and conditions thereof hereby agreed to by the undersigned.
Electronic acceptance of this Agreement pursuant to the Company’s instructions to the Grantee (including through an online acceptance process) is acceptable. 
  

					
	 Dated:
                                         
   
	 		 	
		 	         
	 	  

Grantee’s Signature

			
		 		 	 Grantee’s name and address:

			
		 		 	  

			
		 		 	  

			
		 		 	  

  
 3EX-10.34

 Exhibit 10.34 

Certain identified information has been omitted from this exhibit because it is 

not material and of the type that the registrant treats as private or confidential. 

[***] indicates that information has been omitted. 

SAMSUNG BIOLOGICS CO., LTD. 

PRODUCT SPECIFIC AGREEMENT – CLINICAL PRODUCT DRUG SUBSTANCE 

This Product Specific Agreement (this “PSA”) is made effective as of the date of last signature below (the “PSA Effective
Date”) by and between GreenLight Biosciences, Inc., a Delaware corporation having its principal place of business at 200 Boston Avenue, Suite 1000, Medford, MA 02155 (“Client”) and Samsung Co., Ltd., a Korean corporation
having its principal place of business at 300, Songdo bio-daero, Yeonsu-gu, Incheon, 21987, Republic of Korea (“SBL”). Client and SBL are sometimes
referred to herein individually as a “Party” and collectively as the “Parties”. 
 WHEREAS, Client and SBL
entered into a Master Services Agreement effective November 24, 2021 (the “MSA”) and whereas pursuant to Section 2.1 of the MSA, the Parties wish to enter into this PSA whereby SBL will provide certain Services as detailed
herein; 
 NOW, THEREFORE, the Parties agree as follows: 
  

	1.	 Relationship to the MSA. All capitalized terms not defined in this PSA will have the meanings given to
them in the MSA. This PSA is hereby incorporated by reference into the MSA. 

  

	2.	 Definitions 

  

	 	a.	 “Campaign” shall mean a series of Batches of the Product that are produced in sequence using the same
manufacturing equipment followed by validated cleaning of such equipment and for the purposes of counting the number of Product batches in a Campaigns in a given period, the start date of such Campaign shall be the determining factor. A Campaign
will be deemed to end upon the completion of such cleaning. 

  

	 	b.	 Product: GreenLight Biosciences mRNA COVID vaccine 

 

	 	c.	 “Product Purchase Commitment Shortfall” means the number of Batches of Product falling short of the
Product Purchase Commitment. 

  

	 	d.	 “Year” means each one (1) year period that begins on January 1 and ends on December 31.

  

	3.	 General Information. 

 

	 	a.	 Clinical Product Specification: The Product Specification will be mutually agreed upon and set forth in cGMP
documentation. 

  

	 	b.	 Manufacturing Facility: [***] scale mRNA facility in Plant #3, located at 300, Songdo bio-daero, Yeonsu-gu, Incheon 21987, Republic of Korea. 

  
 1 

	4.	 Raw Materials. 

 

	 	a.	 Client Materials. Client Materials to be supplied by Client to SBL free of charge by itself or a third
party designee. 

  

	 	i.	 List: See Exhibit A: Client Materials 

 

	 	ii.	 Timing of provision of Client Materials to SBL: one month in advance of production unless otherwise agreed to
by the Parties. If Process Validation runs require additional testing, the Parties will mutually agree on the timing. 

  

	 	b.	 Raw Materials. As set forth in Section 4.6.1 of the MSA, the Parties shall finalize the
categorization of Raw Materials to be used in performing the Services of this PSA into (i) Critical Raw Materials, (ii) Dedicated or Customized Raw Materials, and (iii) Other Raw Materials, which list shall form part of this PSA as
Exhibit B. 

  

	 	i.	 Handling Fee for Customized or Dedicated Raw Materials and Other Raw Materials to be procured by SBL at
Client’s expense: [***]. For a Batch, the Handling Fee shall be capped at [***]. 

  

	 	ii.	 Handling Fee for Critical Raw Materials to be procured by SBL at Client’s expense: [***]. For a Batch, the
Handling Fee shall be capped at [***]. 

  

	5.	 Technology Transfer, Manufacturing, and Supply Services. SBL shall perform the Services as set forth in
this Section 5. 

  

	 	a.	 Services.  

  

	 	i.	 SBL shall provide the Services as set forth in Exhibit C in accordance with this PSA, Project Plan, or Scope of
Work. 

  

	 	ii.	 Fees and invoicing. 

  

	 	1.	 Services shall be invoiced upon completion of activities by SBL, or as otherwise agreed by the Parties.

  

	 	2.	 Bulk Drug Product Batches shall be invoiced according to Section 8.2.1 of the MSA. 

 

	 	b.	 Service Fees. In consideration for SBL’s performance of the Services pursuant to this
Section 5, Client shall pay the Service Fees as set forth in Exhibit C. Additional Service Fees and costs may be detailed in an amendment to this PSA or in accordance with the MSA. 

 

	 	c.	 Product Purchase Commitment. 

 

	 	i.	 If the Parties execute a subsequent PSA for commercial production of Bulk Drug Product of the Product, the
Parties agree that such subsequent PSA shall contain the following Product Purchase Commitment: [***]. Such PSA shall also include a term such that if Client makes an improvement to the Product manufacturing process which reduces facility time, the
Parties shall in good faith reevaluate the Batch price. 

  

  
 2 

	 	ii.	 This PSA’s Product Purchase Commitment is [***]. Upon execution of this PSA, Client shall issue a Purchase
Order for the Product Purchase Commitment, and such Purchase Order shall be fully binding on a minimum take or pay basis. 

  

	 	iii.	 Each Year, Client shall pay to SBL the price set forth in this PSA for each of the Product Purchase Commitment
Shortfall, if any. For any Year for which a Product Purchase Commitment Shortfall payment is owed to SBL no later than December 31 of the Year when there is a Product Purchase Commitment Shortfall for such Year. 

 

	6.	 2023 Capacity Right of First Refusal. [***]. For clarity after such right expires the Parties may nevertheless
agree on the sale of such capacity to Client. 

  

	7.	 Regulatory Approvals. The Regulatory Approvals covered by this PSA are the Food and Drug Administration
(FDA), European Medicines Evaluation Agency (EMEA), and South African Health Products Regulatory Authority (SAHPRA) 

  

	8.	 Storage. Pursuant to Section 4.12.2(a)(ii) of the MSA, if Client does not direct SBL to prepare
Manufactured Commercial Product to be picked up by Client or Client’s designated carrier with a pick-up date within thirty (30) days of Client’s or Client’s designee’s receipt of the
Batch Related Documents, SBL shall store the Commercial Product at the Warehouse and Client shall pay storage fees to SBL for the period of storage at the Warehouse until the actual delivery date. Storage fees shall be as follows: [***] per month
per 10L bag. 

  

	9.	 Outbound Technology Transfer. Once during the term of this PSA or upon its termination, SBL shall
provide support for outbound technology transfer to a Client facility or a Third Party’s facility designated by the Client. The outbound technology transfer request must be made with at least six (6) months prior written notice. The scope
of such outbound technology transfer will be mutually agreed upon scope of work but in no event shall SBL be obligated to provide more than two full time employee equivalent (“FTE”) months. 

 

	10.	 Termination Fee for Termination without Cause. In the event Client terminates this PSA pursuant to MSA
Section 14.2.1, the termination fee payable by Client shall be as follows: the value of the Product Purchase Commitment, to the extent not already paid prior to termination. 

 

	11.	 Limitation of Liability. Notwithstanding Section 13.2 of the MSA, except with respect to Damages or
allowable indirect damages arising under or in connection with this PSA arising out of (i) breaches of Sections 9 and 10 of the MSA; (ii) instances of gross negligence or willful misconduct (which shall not include Materials Claims); (iii)
Materials Claims; and/or (iv) third party death or bodily injury caused by SBL to Client employees or contractors who may visit SBL sites, Client agrees that SBL’s aggregate total liability to Client in respect of any Ordinary Claims
arising out of this PSA shall be 

  
 3 

	 	
capped at an amount equal to [***] the amounts payable by Client to SBL pursuant to this PSA. Client agrees that SBL’s aggregate total liability to Client in respect of any Materials Claims
arising out of this PSA shall be capped at an amount equal to [***] of the amounts payable by Client to SBL under such PSA. SBL’s aggregate total liability to Client pursuant to this PSA for Materials Claims and Ordinary Claims combined shall
never exceed [***] of the amounts payable by Client to SBL under such PSA. 

  

	12.	 Term. This PSA will commence as of the PSA Effective Date and will continue in full force and effect
until December 31, 2026 or unless earlier terminated in accordance with the termination provisions of this PSA and/or the MSA. 

The Parties have entered into this PSA as of the PSA Effective Date by their respective duly authorized representatives. 

 

									
	SAMSUNG BIOLOGICS CO., LTD.	 		 	GREENLIGHT BIOSCIENCES, INC.
					
	By:	 	 /s/ John Rim
	 		 	By:	 	 /s/ Andrey Zarur

	Name:	 	John Rim	 		 	Name:	 	Andrey Zarur
	Title:    	 	CEO & President	 		 	Title:    	 	CEO

  
 4 

 Exhibit A: Client Materials 

[***] 

  
 5 

 Exhibit B: Categorization of Raw Materials 

[***] 

  
 6 

 Exhibit C: Services 

Estimated Project Timeline 
  

	 	•	 	 Actual activity start dates may adjusted subject to the dates which Parties mutually agree after the execution of
this PSA 

 [***] 
 mRNA Manufacturing Price

  

							
	 Service
	  	 Price (USD)
	  	 
				
	Stage 1	  	Project Management	  	[***]	  	Per year
				
	Stage 2	  	Technology Transfer of IVT/LNP	  	[***]	  	One-time fee
				
	Stage 3	  	Analytical Method Transfer	  	[***]	  	One-time fee, based on the list of analytical methods
				
	Stage 4	  	Process Development and Scale-up	  	[***]	  	 To be further discussed
 Highly scope
dependent

				
	Stage 5	  	Engineering Run	  	[***]	  	Per Bulk Drug Product batch
				
	Stage 6	  	Process Characterization	  	[***]	  	 To be further delivered
 Highly scope
dependent

				
	Stage 7	  	cGMP Run (Clinical or Process Validation)	  	[***]	  	Per Bulk Drug Product batch
	
	OPTIONAL ACTIVITIES
				
	Stage 8	  	Process Validation Planning and Study Execution	  	[***]	  	One-time fee
				
	Stage 9	  	 Process Validation Run
 (with option to release
for human use)
	  	[***]	  	Per Bulk Drug Product batch
				
	Stage 10	  	Cleaning Validation	  	[***]	  	[***]
				
	Stage 11	  	Support for Regulatory Applications	  	[***]	  	Per filing
				
	Stage 12	  	PAI Preparation & Inspection	  	[***]	  	Per inspection
				
	Stage 13	  	PAI Campaign	  	[***]	  	Per Bulk Drug Product batch
				
	Stage 14	  	Commercial Run	  	[***]	  	 Tier 1: [***]
 Tier 2: [***]

Tier 3: [***]

				
	Optional	  	Stability Testing	  	[***]	  	 Stability Set-up Fee

Per storage condition; per time point

				
	Optional	  	pDNA synthesis starting in [***]	  	[***]	  	

  

	*	 Service fee for Stage 3, 4, 6, and 10 shall be updated based on further discussion with GreenLight Biosciences

 PRICING AND PAYMENT ASSUMPTIONS 

Standard pricing and payment terms are listed below. 
  

	 	•	 	 The price is based on information provided in the RFP regarding the product and manufacturing process [***].
Further communication between Samsung Biologics and GreenLight Biosciences regarding the specifics of the project may result in changes to the scope of work and associated price. Any change in scope or price will be documented via an amendment to
this PSA. 

  
 7 

	 	•	 	 Tiered batch price is based on a single campaign per year and resets [***]. 

 

	 	•	 	 Commercial Run pricing is based on [***]. Further process details provided by GreenLight Biosciences may impact
the pricing. 

  

	 	•	 	 The assays listed in Appendix A2: Analytical Methods for Covid-19 Vaccine
DS will be transferred. 

  

	 	•	 	 Samsung Biologics will conduct Mycoplasma testing at Samsung Biologics’ QC (Quality Control) Laboratory, if
requested. 

  

	 	•	 	 The proposed prices are based on regulatory requirements that complies with FDA, EMEA, Canada, SAHPRA, and PMDA.
Prices may change depending on the additional requirements necessary to comply with other regulatory authorities. 

  

	 	•	 	 Unless otherwise noted, all batches are intended for human use and will be aseptically filled, 100% inspected,
bulk packaged, shipped and released for further processing to the client. Client or Client’s designee is responsible for final product release. 

  

	 	•	 	 Samsung Biologics will support shipping validation execution activities by following the Client
packaging/preparation instructions; Client is accountable for shipping validation, strategy, execution and documentation. 

  
 8 

 Exhibit D: Scope of Work 

[***] 

  
 9

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00338-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00338-of-00352.parquet"}]]